Call Now Open
2026 Oxford-Harrington Rare Disease Scholar Award
January 15, 2026
The Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, is seeking highly innovative projects for its 2026 Rare Disease Scholar Award, which accelerates promising therapeutics discoveries from academic labs...
Continue Reading
July 09, 2025
Published in NatureAbstractDecreased brain levels of coenzyme Q10 (CoQ10), an endogenously synthesized lipophilic antioxidant,, underpin encephalopathy in primary CoQ10 deficiencies, and are associated with common neurodegenerative diseases and the ageing process,. CoQ10 supplementation does not increase CoQ10 pools in the... Continue Reading
June 24, 2025
Harrington Discovery Institute and the American Society for Clinical Investigation seek nominations to recognize an outstanding achievement by a physician-scientist Continue Reading
June 19, 2025
Published in Cell Chemical BiologySignificanceEnzymes that regulate oncogenic protein function through the addition of post-translational modifications (PTMs) represent promising targets for the development of cancer therapeutics. N-glycosylation is a critical PTM that occurs in the lumen of the endoplasmic reticulum (ER) and... Continue Reading
June 04, 2025
The former prime minister has called for children admitted to paediatric care to undergo genome sequencing as part of a drive to cure 40 rare diseases Continue Reading
June 03, 2025
Drug development grant will advance 10 physician-scientists’ discoveries toward the clinic Continue Reading
May 23, 2025
Scientific researchers and leaders from across the globe gathered in Cleveland, Ohio to discuss progress being made in drug development for a variety of conditions, including Alzheimer’s and rare diseases. Continue Reading
May 21, 2025
Alzheimer’s disease (AD) and traumatic brain injury (TBI) are currently untreatable neurodegenerative disorders afflicting millions of people worldwide. These conditions are pathologically related, and TBI is one of the greatest risk factors for AD. Continue Reading
May 01, 2025
Call for proposals on proteostasis and senescence are particularly encouraged, alongside all novel approaches to treating Alzheimer’s disease Continue Reading
April 29, 2025
Mr. Jafar is a distinguished international business leader and co-founder of the Loulou Foundation Continue Reading
April 16, 2025
Unique program for physician-scientists to advance promising discoveries into medicines Continue Reading